Lewes, DE — (PRESS RELEASE JET) — 10/30/2017 — Raynauds Disease – Pipeline Review, H2 2017, provides an overview of the Raynauds Disease (Cardiovascular) pipeline landscape.

Raynauds disease is a common condition that affects the blood supply to certain parts of the body, usually the fingers and toes. Predisposing factors include age, gender, family history and smoking. Symptoms include fingers, toes, ears, or nose to become white, and then turn blue. Treatment includes vasodilator, alpha blockers and calcium channel blockers.

Report Highlights

Raynauds Disease – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Raynauds Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Raynauds Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Unknown stages comprises 1 molecules, respectively.

Raynauds Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Raynauds Disease (Cardiovascular).

– The pipeline guide reviews pipeline therapeutics for Raynauds Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Raynauds Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Raynauds Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Raynauds Disease (Cardiovascular)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Raynauds Disease (Cardiovascular).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Raynauds Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 48 pages “Raynauds Disease – Pipeline Review, H2 2017” report covers Introduction, Report Coverage, Raynauds Disease – Overview, Raynauds Disease – Therapeutics Development, Raynauds Disease – Therapeutics Assessment, Raynauds Disease – Companies Involved in Therapeutics Development, Product Description, Raynauds Disease – Dormant Projects, Appendix. This report Covered Companies – Allergan Plc, Apricus Biosciences Inc, Covis Pharmaceuticals Inc.

Please visit this link for more details: https://www.marketresearchreports.com/global-markets-direct/raynauds-disease-pipeline-review-h2-2017

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Restenosis – Pipeline Review, H2 2017 – Visit at – https://www.marketresearchreports.com/global-markets-direct/restenosis-pipeline-review-h2-2017

Atopic Dermatitis – Pipeline Review, H2 2017 – Visit at – https://www.marketresearchreports.com/global-markets-direct/atopic-dermatitis-pipeline-review-h2-2017

About Market Research Reports, Inc.
Market Research Reports® Inc. is world’s largest store offering quality market research, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.

Contact us for your market research requirements: http://www.marketresearchreports.com/contact

Powered by WPeMatico